| Stereochemistry | UNKNOWN |
| Molecular Formula | C14H14ClN3O4S2 |
| Molecular Weight | 387.862 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NS(=O)(=O)C1=CC2=C(NC(CC3=CC=CC=C3)NS2(=O)=O)C=C1Cl
InChI
InChIKey=BWSSMIJUDVUASQ-UHFFFAOYSA-N
InChI=1S/C14H14ClN3O4S2/c15-10-7-11-13(8-12(10)23(16,19)20)24(21,22)18-14(17-11)6-9-4-2-1-3-5-9/h1-5,7-8,14,17-18H,6H2,(H2,16,19,20)
Approval Year
PubMed
Sample Use Guides
Adult Dose for Hypertension: In combination with diuretics: Initial dose: 2.5 mg orally once a day. If feasible, the diuretic should be discontinued 2 to 3 days prior to initiation of therapy with enalapril. If required, diuretic therapy may be gradually resumed. Parenteral: 1.25 to 5 mg IV over a 5 minute period every 6 hours
Route of Administration:
Oral
The NHIK 3025 cell line (Norsk Hydro Institutt for Kreftforskning), a human in situ carcinoma of the cervix cell line, was used to investigate the benzylhydrochlorothiazide for its potential phototoxic properties. Cell death following UVA irradiation and dependent on test substance concentration was observed in the presence of benzylhydrochlorothiazide. This compound was phototoxic at 0.25 mM and higher.
ACTIVE MOIETY
